Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**TumorSelect Paclitaxel** is a targeted formulation of the taxane chemotherapy agent paclitaxel, designed for tumor-selective delivery to enhance efficacy and reduce systemic toxicity. Paclitaxel stabilizes microtubules, preventing depolymerization and disrupting mitotic spindle function, leading to G2/M phase arrest and apoptosis in rapidly dividing cancer cells. Developed as a novel delivery system, it aims to concentrate the drug at the tumor site for improved therapeutic outcomes in solid tumors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TumorSelect Paclitaxel.